Opportunistic infections after treatment with monoclonal antibodies [Opportunistische infektionen nach therapie mit monoklonalen antikörpern]

被引：8

作者：

Cornely O.A. ^{[1
,2
]}

Ullmann A.J. ^{[1
]}

Karthaus M. ^{[1
]}

机构：

[1] Hämatologie, Onkologie, Klin. der Universität Köln

[2] Hämatologie, Onkologie, Klin. der Universität Köln

来源：

Wiener Medizinische Wochenschrift | 2004年 / 154卷 / 9-10期

关键词：

Cytomegalovirus; Monoclonal antibody; Opportunistic infection; Pneumocystis carinii pneumonia; Prophylaxis; Varizella zoster virus;

D O I：

10.1007/s10354-004-0067-y

中图分类号：

学科分类号：

摘要：

During recent years the therapeutic indications of monoclonal antibodies are on the increase. Most monoclonal antibodies are immunosuppressants. Thus, therapeutic successes are accompanied by an increase of serious infections. Closest cooperation between the haematologist/oncologist and the infectious diseases specialist is a prerequisite for the successful outcome of treatment of the individual patient. Rituximab and alemtuzumab especially pave the way for a variety of opportunistic infections. Prophylactic drugs directed against bacterial infections and invasive fungal infections have not been proven to be useful. Although the efficacy of prophylactic cotrimoxazole against Pneumocystis carinii pneumonia has not been thoroughly examined in this setting, it is usually given at a dose of two double-strength tablets every other day. Whether reactivation of herpes simplex and varizella zoster can be influenced prophylactically has not been studied in randomised trials. In case of fever and detection of cytomegalovirus reactivation preemptive therapy should be given.

引用

页码：209 / 217

页数：8

共 49 条

[31]

Avivi I., Chakrabarti S., Milligan D.W., Waldmann H., Hale G., Osman H., Et al., Incidence and outcome of adenovirus disease in transplant recipients after reduced-intensity conditioning with alemtuzumab, Biol Blood Marrow Transplant, 10, 3, pp. 186-194, (2004)

[32]

Faderl S., Thomas D.A., O'Brien S., Garcia-Manero G., Kantarjian H.M., Giles F.J., Et al., Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies, Blood, 101, 9, pp. 3413-3415, (2003)

[33]

Perez-Simon J.A., Kottaridis P.D., Martino R., Craddock C., Caballero D., Chopra R., Et al., Nonmyeloablative transplantation with or without alemtuzumab: Comparison between 2 prospective studies in patients with lymphoproliferative disorders, Blood, 100, 9, pp. 3121-3127, (2002)

[34]

Martino P., Girmenia C., Micozzi A., De Bernardis F., Boccanera M., Cassone A., Et al., Prospective study of Candida colonization, use of empiric amphotericin B and development of invasive mycosis in neutropenic patients, Eur J Clin Microbiol Infect Dis, 13, 10, pp. 797-804, (1994)

[35]

Cornely O.A., Bohme A., Buchheidt D., Glasmacher A., Kahl C., Karthaus M., Et al., Prophylaxis of invasive fungal infections in patients with hematological malignancies and solid tumors guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Ann Hematol, 82, 2 SUPPL., pp. 186-200, (2003)

[36]

Alemtuzumab, Zusammenfassung der Merkmale Eines Arzneimittels, (2001)

[37]

Rituximab, Zusammenfassung der Merkmale Eines Arzneimittels, (1998)

[38]

Schulz H., Klein S.K., Rehwald U., Reiser M., Hinke A., Knauf W.U., Et al., Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia, Blood, 100, 9, pp. 3115-3120, (2002)

[39]

Hughes W.T., Rivera G.K., Schell M.J., Thornton D., Lott L., Successful intermittent chemoprophylaxis for pneumocystis carinii pneumonitis, N Engl J Med, 316, 26, pp. 1627-1632, (1987)

[40]

O'Brien S.M., Kantarjian H.M., Thomas D.A., Cortes J., Giles F.J., Wierda W.G., Et al., Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia, Cancer, 98, 12, pp. 2657-2663, (2003)

← 1 2 3 4 5 →